Exhalation Technology Announces Updated Clinical Trial Data for its Rapid Covid-19 Diagnostic Test
Cambridge, England, 4 January 2021 – Exhalation Technology (ETL), a Cambridge, UK-based company, announced updated results from its...
top of page
Sage Group News
Exhalation Technology Launch Clinical Trial for CoronaCheck™ – A Rapid Covid-19 Diagnostic Test
Cambridge, England, 2 November 2020 – Exhalation Technology (ETL), a Cambridge, UK-based company, announced the start of a large clinical...
Exhalation Technology Announces Search for Partners for its Covid-19 Rapid Diagnostic Test
Cambridge, England, 24 September 2020 – Exhalation Technology has appointed The Sage Group to lead the partnering program for its novel...
Sage Represents Respira Therapeutics - Opportunity to License RT234, A Late Stage Asset for Pulmonar
The Sage Group is working with Respira Therapeutics (“Respira”; http://respiratherapeutics.com/) to identify clinical and commercial...
Sage Represents DBM: An Opportunity to Acquire or Partner with a Revenue Generating Pre-Clinical CRO
The Sage Group is pleased to announce it is representing Discovery Biomed (“DBM”; https://discoverybiomed.com/). DBM is a...
The Sage Group Expands Team in Japan with Hideyuki Hirama of Gemseki in Tokyo As Partner
London, New York and Tokyo, July 6 2020 - The Sage Group Inc. today announced that Gemseki Japan, led by Hideyuki Hirama, will join its...
Sage Represents Cancer Prevention Pharmaceuticals: A Late Stage, $Billion Orphan Product Opportunity
Sage’s client, Cancer Prevention Pharmaceuticals (“CPP”; www.canprevent.com),is a late clinical stage company developing a unique, oral,...
Sage Group Represents Squarex's SQX770: A Novel Immunologic Approach for the Prevention of Cold
The Sage Group is pleased to announce it has been appointed to represent a product from Squarex LLC, SQX770, the only product which...
bottom of page